📊 CPMD Key Takeaways
Is Cannapharmarx, Inc.. (CPMD) a Good Investment?
CPMD exhibits severe financial distress with negative stockholders' equity of -$22.5M, indicating the company is technically insolvent and liabilities exceed all assets. The company is burning cash at an alarming rate with -$1.9M operating cash flow against only $1.2K in cash reserves, creating an immediate liquidity crisis. Negative gross margins of -127.8% suggest fundamental business model failure with the company losing money on every dollar of revenue.
Fundamentals are extremely weak: the company is generating negative gross profit, deeply negative operating and net margins, and burning cash from operations with essentially no liquidity buffer. The balance sheet is highly distressed, with negative equity, a current ratio of 0.05x, and liabilities far exceeding assets, which raises serious doubts about financial sustainability and the quality of any reported revenue base.
Why Buy Cannapharmarx, Inc.. Stock? CPMD Key Strengths
- Minimal capital expenditure requirements suggest asset-light operations
- Some revenue generation of $1.2M indicates ongoing business activity
- No recent insider sales in last 90 days
- Reported revenue of $1.22M shows the business has some commercial activity
- Capital expenditure is minimal, which limits additional cash drain from investment spending
- Net loss appears flat year over year, suggesting losses did not accelerate further in the latest period
CPMD Stock Risks: Cannapharmarx, Inc.. Investment Risks
- Negative stockholders' equity of -$22.5M indicates technical insolvency
- Critical liquidity crisis with $1.2K cash against $34.1M liabilities and $7.0M long-term debt
- Negative gross margin of -127.8% indicates fundamental business model failure
- Operating cash burn of -$1.9M per period with minimal cash runway
- All profitability metrics deeply negative with net margin of -292.7%
- Current ratio of 0.05x indicates severe inability to meet short-term obligations
- Negative gross margin indicates the core business is not economically viable at current scale
- Severe liquidity stress with only about $1.21K in cash and very weak current and quick ratios
- Negative equity and heavy liabilities relative to assets create substantial solvency risk
Key Metrics to Watch
- Cash position and runway to insolvency
- Gross margin trajectory toward positive territory
- Operating cash flow stabilization
- Gross margin improvement toward positive territory
- Operating cash flow and ending cash balance
Cannapharmarx, Inc.. (CPMD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
CPMD Profit Margin, ROE & Profitability Analysis
CPMD vs Healthcare Sector: How Cannapharmarx, Inc.. Compares
How Cannapharmarx, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Cannapharmarx, Inc.. Stock Overvalued? CPMD Valuation Analysis 2026
Based on fundamental analysis, Cannapharmarx, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Cannapharmarx, Inc.. Balance Sheet: CPMD Debt, Cash & Liquidity
CPMD Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Cannapharmarx, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.02 indicates the company is currently unprofitable.
CPMD Revenue Growth, EPS Growth & YoY Performance
CPMD Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $312.2K | $188.4K | $0.00 |
| Q2 2025 | N/A | -$1.4M | $0.00 |
| Q1 2025 | $25.8K | -$690.6K | $0.00 |
| Q3 2024 | N/A | $188.4K | $0.00 |
| Q1 2024 | N/A | -$1.4M | $0.00 |
| Q3 2023 | N/A | -$564.4K | $0.00 |
| Q2 2023 | N/A | -$1.4M | $-0.01 |
| Q1 2023 | N/A | -$1.4M | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Cannapharmarx, Inc.. Dividends, Buybacks & Capital Allocation
CPMD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Cannapharmarx, Inc.. (CIK: 0001081938)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CPMD
What is the AI rating for CPMD?
Cannapharmarx, Inc.. (CPMD) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 96% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CPMD's key strengths?
Claude: Minimal capital expenditure requirements suggest asset-light operations. Some revenue generation of $1.2M indicates ongoing business activity. ChatGPT: Reported revenue of $1.22M shows the business has some commercial activity. Capital expenditure is minimal, which limits additional cash drain from investment spending.
What are the risks of investing in CPMD?
Claude: Negative stockholders' equity of -$22.5M indicates technical insolvency. Critical liquidity crisis with $1.2K cash against $34.1M liabilities and $7.0M long-term debt. ChatGPT: Negative gross margin indicates the core business is not economically viable at current scale. Severe liquidity stress with only about $1.21K in cash and very weak current and quick ratios.
What is CPMD's revenue and growth?
Cannapharmarx, Inc.. reported revenue of $1.2M.
Does CPMD pay dividends?
Cannapharmarx, Inc.. does not currently pay dividends.
Where can I find CPMD SEC filings?
Official SEC filings for Cannapharmarx, Inc.. (CIK: 0001081938) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CPMD's EPS?
Cannapharmarx, Inc.. has a diluted EPS of $-0.01.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CPMD a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Cannapharmarx, Inc.. has a STRONG SELL rating with 96% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CPMD stock overvalued or undervalued?
Valuation metrics for CPMD: ROE of N/A (sector avg: 15%), net margin of -292.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CPMD stock in 2026?
Our dual AI analysis gives Cannapharmarx, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CPMD's free cash flow?
Cannapharmarx, Inc..'s operating cash flow is $-1.9M, with capital expenditures of $0.0. FCF margin is -151.2%.
How does CPMD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -292.7% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.05 (avg: 2).